Conference Agenda
Day 1, Monday, September 22, 2014
8:15 a.m. - 8:30 a.m.
Welcome By Co-Chairs
Michael M. Buchman, Motley Rice, New York
Marvin A. Miller, Miller Law LLC, Chicago
8:30 a.m. - 9:30 a.m.
An Overview of the Hatch-Waxman Act
• The Purpose of the Act
• The Key Provisions
• The Automatic Stay Provision
• Significance of the First Filer Status and Litigation between Generics Companies
Mitchell Breit, Simmons Hanly Conroy LLC, New York
Jeffrey M. Padwa, Providence City Solicitor, Providence, RI
Terence S. Ziegler, Kessler Topaz Meltzer & Check, LLP, Radnor, PA
9:30 a.m. - 10:15 a.m.
Patent Issues Related to Generic Drug Cases
• The Abbreviated New Drug Application and the Sherman Antitrust Act
• The Scope of the Patent
Debra Josephson, Roberts Law Firm, P.A., Little Rock, AR
Samuel O. Patmore, Stearns Weaver Miller Weissler Alhadeff & Sitterson, Miami
10:30 a.m. - 11:30 a.m.
The Supreme Court Decision in Actavis from the Plaintiff’s Perspective
• How District Courts Should, and Should Not, Implement the Rule of Reason in a Case Alleging Reverse Payments Under Actavis
• The Role of the Court vs. the Finder of Fact
• Burdens of Production and Persuasion Borne by Plaintiff and Defendant, Respectively
• Defenses That are Cognizable vs. Non-Cognizable
Peter Kohn, Faruqi & Faruqi LLP, Philadelphia
David F. Sorensen, Berger & Montague, P.C., Philadelphia
11:30 a.m. - 12:30 p.m.
The Supreme Court Decision in Actavis from the Defense Perspective
• Patents and Reverse Payment Agreements: What Constitutes Reverse Payment
• Where is the Balance Between Antitrust, Hatch-Waxman Regulatory Scheme, Patent Law, and Encouragement of Settlements?
• Role of Patent Merits in a Rule of Reason Analysis
• How are the Lower Courts Applying Actavis?
Robert A. Milne, White & Case LLP, New York
Edward D. Rogers, Ballard Spahr LLP, Philadelphia
Stephen J. Kastenberg, Ballard Spahr LLP, Philadelphia
1:45 p.m. - 2:45 p.m.
Class Certification and Trial Issues in Generic Drug Cases
Thomas M. Sobol, Hagens Berman Sobol Shapiro LLP, Boston
Steve Shadowen, Hilliard | Shadowen LLC, Mechanicsburg, PA
3:00 p.m. - 3:45 p.m.
Consolidation and Coordination in Generic Drug Cases
• MDL-Related Issues Unique to Pay for Delay Cases
• What to Anticipate in Arguing Before the MDL Panel
• Selection of the MDL Transferee Forum
• Strategies for Coordination Between Direct and Indirect Purchasers
Daniel C. Girard, Girard Gibbs LLP, San Francisco
Lisa J. Rodriguez, Schnader Harrison Segal & Lewis LLP, Cherry Hill, NJ
3:45 p.m. - 4:45 p.m.
Settlement of Class Action Cases
• Damage Modeling in Antitrust Litigation
• Negotiation Lessons Learned from the Defense and Purchaser Perspectives
• Claims Processing and Administration
• Court Involvement in Class Action Settlements as "Fiduciary of the Class"
Sheila L. Birnbaum, Quinn Emanuel Urquhart & Sullivan LLP, New York
Donald A. Migliori, Motley Rice, Providence, RI
